Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Corbus Pharmaceuticals adds two mAbs to its pipeline

By Brian Buntz | June 2, 2021

Corbus PharmaceuticalsCorbus Pharmaceuticals (NSDQ:CRBP) is expanding its pipeline in immuno-oncology and fibrotic disease with licensing deals for two monoclonal antibodies (mAbs), which it has named CRB-601 and CRB-602.

Both mAbs target integrins that inhibit activation of transforming growth factor-beta (TGF-β), a cytokine linked to inflammation, fibrosis and cancer. “TGF beta needs to be activated from its latent form to exert its biologic activities,” explained Dr. Barbara White, Corbus’s chief medical officer and director of research.

CRB-601 is a high potency anti-alpha V beta 8 (anti-avb8 mAb) antibody that the company acquired from the University of California, San Francisco. “We believe that CRB-601 could offer advantages over competitor approaches and expect to initiate Phase 1 clinical studies next year,” said Corbus CEO Yuval Cohen.

The CRB-602 antibody inhibits both alpha V beta 6 and alpha V beta 8. Corbus acquired that antibody from Panorama Research Inc. (Sunnyvale, Calif.). Corbus believes the mAb has potential for fibrotic diseases.

“Some human epithelial malignancies or carcinomas express alpha V beta 8 themselves, which activates latent TGF beta in their microenvironment,” White added. “Importantly, overexpression of alpha V beta 8 by tumor cells and expression of TGF beta in tumors have both been linked to poor clinical outcomes.”

Corbus plans to launch clinical research for CRB-602 next year.

“These two new programs fit neatly into our pipeline, alongside our existing programs, which focus on the endocannabinoid system,” Cohen said. “They align with and extend the disease areas we are pursuing and will benefit from our expertise in drug development.”

In the combined terms of the two exclusive licensing agreements, Corbus has agreed to pay $2 million upfront. Additionally, it has offered to make potential development and sales milestone payments of up to $206,000,000 while paying low single-digit royalties on sales.

 


Filed Under: clinical trials, Drug Discovery, Immunology, Oncology
Tagged With: Corbus Pharmaceuticals, CRB-601, CRB-602, immuno-oncology
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE